Thursday, November 24, 2022 8:59:56 AM
A good example for you is any of the RSV therapeutics- all failed. Great exposures and great potencies - no translation. My point is that just because something is potent and has good PK, that doesn’t mean it will translate into a cure for an acute infection. Remember, this is a phase 2 in standard risk, highly seropositive population with a safety primary endpoint. A very hesitant step, you must agree.
Yes this is a validated MoA. But, they are not showing their full hand. Again- where is the animal efficacy data? They must have it. Everyone else has shown this. If someone was buying, they would have already bought it. Certainly cheap enough here.
Recent ENTA News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 12:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:20:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:18:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:17:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:14:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 08:05:29 PM
- Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference • Business Wire • 03/03/2026 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/23/2026 05:15:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:33:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:31:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:29:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:28:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:27:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/11/2026 09:43:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/11/2026 09:00:44 PM
- Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting • Business Wire • 02/10/2026 12:00:00 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 • Business Wire • 02/09/2026 09:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/26/2026 09:10:39 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/26/2026 09:05:32 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 01/20/2026 09:42:25 PM
- Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook • Business Wire • 01/08/2026 12:00:00 PM
- Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference • Business Wire • 01/05/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2025 11:47:53 PM
Eco Science Solutions Integrates IDScan.net's DIVE Into Herbo Pay to Power Identity Verification, Compliance, and Fraud Prevention • ESSI • Mar 27, 2026 12:01 PM
The Crypto Company Acquires FRAME Blockchain's Technology, An "Interstate Highway" Liquidity Layer for Crypto Commerce • CRCW • Mar 26, 2026 12:28 PM
Resilient Energy Inc. Enters LOI Negtiations for Second Acquisition; First Acquisition Nears Closing • RENI • Mar 26, 2026 10:30 AM
Alliance Creative Group (ACGX) Releases 2025 Annual Financial and Disclosure Report • ACGX • Mar 26, 2026 8:30 AM
Isiah Enterprises Activates Scalable Materials Platform Targeting $900B+ Global Market Opportunity; Initiates Strategic Partner Alignment Phase • OWPC • Mar 25, 2026 9:07 AM
ECGI Signs Definitive $25 Million Agreement to Acquire RezyFi • ECGI • Mar 24, 2026 8:30 AM
